Mentanine® - Natural Formulation Developed To Improve Brain Health, Backed By Pre-Clinical Trials
Mentanine®, supported by (cannabidiol “CBD” + IP formula) – molecules bond and synergistically attach to PPAR receptors allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trials. Mentanine® is a natural pure plant-based pharmaceutical-grade cannabidiol (CBD) isolate plus natural omega-3 ingredients IP formula. Pre-clinical trial results have demonstrated that it effectively crosses the blood-brain barrier “BBB” to target neurological conditions such as anxiety, depression, PTSD, and addiction. It is an attractive natural mental health solution.
-
Most popular related searches
Mental Health Conditions
Mentanine® is highly bioavailable and is a fast-acting formula that has the ability to act on inflammation within the Central Nervous System (CNS), the brain. This type of inflammation contributes to neurological conditions such as Anxiety, Depression, Schizophrenia, PTSD, or Addiction.
Scientifically Developed Formulation
- Molecules synergistically bind to PPAR receptors that facilitate Mentanine® to cross the blood-brain barrier (BBB) for ultimate and consistent efficacy.
- Pharmaceutical-grade – highly concentrated cannabidiol (CBD) isolate.
- Essential Fatty Acids (EFAs) with a specific concentration of active Omega-3 ingredients
- Efficient food-grade supply chain process – from cultivation and processing to distribution.
- GMP manufacturing facility, with ISO certified processing.
Small Dosage
Mentanine® may be formulated in a powder or liquid form. Administered orally as either a capsule or sublingually (under the tongue) as a tincture with the water-soluble solution. One Mentanine® powder-filled capsule contains 21.5 mg of water-soluble CBD + IP formula. The synergistic effect resulting from CBD with omega-3 active ingredients is > 10 times more effective than pure water-soluble CBD.
To ensure safety and effectiveness we advise first-time users to consult their physicians.,especially patients taking antidepressants. Although our table may not list all antidepressants that can be affected by CBD, it demonstrates a warning to not mix anti-depressing drugs with CBD.
Product Details
MENTANINE®With:
- New! Formulation developed to improve brain health
- Scientifically-backed by pre-clinical trials
- Many times, more effective than Pure CBD
Double-Acting Formula
Acts on the central nervous system (the brain) and the endocannabinoid system.
The Advantages
The advantage of Mentanine® is its effectiveness and efficacy, – only a small oral dose of 30mg to 60mg of CBD daily is recommended by our scientists, as compared to a wide range of oral doses from 100mg/day to 800mg/day.
Additional Information:
- Weight: N/A
- Capsules: 60 capsules, 180 capsules
Mentanine Formula
Dr. Laviolette has made an amazing discovery:
New Pathway Discovery: The formulated ingredients bond and synergistically attach to the PPAR receptor allowing the Mentanine® formula to cross the blood-brain barrier “BBB” to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this.
With improved efficacy, Mentanine® addresses neurological conditions such as anxiety, depression, PTSD, and addiction.
Mentanine® (plant-based cannabidiol “CBD” and natural IP formula)
- the central nervous system (the brain) and
- the endocannabinoid system (receptors)
Dr. Laviolette stated, “Our CBD-based formulation works synergistically and has multiple times the efficacy compared to other approved CBD products on the market. This discovery sets the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects. There is strong evidence that this formulation is also a very promising anti-epilepsy treatment, which I believe makes the formulation even more promising for these applications.”
Pre-Clinical Trials
- Indicated 10 times + the efficacy as compared to CBD alone
- Reduced Anxiety, Depression, PTSD, and Addictive effects
- Showed significant reduction of inflammation, which could be beneficial for pain management.
Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience. Oct. 2020.
Mentanine® can be administrated with a significantly faster rate of absorption and significantly smaller doses compared to other CBD medications, therefore, reducing or even eliminating the negative side effects of liver toxicity caused by the high consumption of CBD oils available today.
One of The Characteristics of dopamine cells is that they have a tonic mode of firing and burst mode of firing. Therefore, we analyze both the frequency and burst changes following infusions.
The left graph is looking at the frequency of VTA dopamine cells. The Y-axis is frequency %baseline). Just to clarify what this means: if we look at the 100ng CBD group, it shows about 85%. This means that with an intra-NAc infusion of 100ng CBD, the dopamine cell would decrease in frequency by about 15%.
The right graph is looking at the difference in burst %. A burst is a group of signals occurring in a short period of time. Specifically, we define a burst to be an event where 2 spikes occur within 80 ms. Burst does not occur very often, so it is inaccurate to use the % baseline in the Y-axis (if 1 burst occurs during pre-infusion and 0 bursts during post-infusion, that’s a 100% decrease although it is only 1 less event). Instead, we got the number of bursts that occurred during the pre-infusion recording and determined the number of spikes that occurred in those bursts, and divided that by the total number of spikes that occurred during the pre-infusion recording. We did the same for the post-infusion recording and found the difference between those two values.
One-way Analysis of Variance (ANOVA) revealed that these groups are not significantly different. However, we see that 100ng caused a decreasing trend in VTA dopamine frequency.
Experiment 2
In the second experiment, we combined a lower dose of CBD (50ng) with omega-3 fatty Acids.
Left graph: one-way analysis of variance (ANOVA) revealed that the groups are significantly different. While 50ng CBD and 0.5nmol of omega-3 were ineffective by themselves, post-hoc analysis revealed the combination of CBD and omega-3 caused a significant decrease in VTA dopamine activity.
Experiment 3
In experiment 3, we wanted to see if we can replicate the results of experiment 2 with lower doses of CBD and Omega-3.
Left graph: one-way analysis of variance (ANOVA) did not yield a significant effect (p=0.194), however, post-hoc analysis revealed that while 1ng CBD and 0.25nmol Omega-3 caused a significant decrease in VTA dopamine activity compared to vehicle.
The addition of T007 to this combo blocked its effect which suggests that the CBD with Omega-3 may produce their effect through PPARg.
Customer reviews
No reviews were found for Mentanine® - Natural Formulation Developed To Improve Brain Health, Backed By Pre-Clinical Trials. Be the first to review!